Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) is expected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Arbutus Biopharma to post earnings of ($0.0550) per share and revenue of $0.8290 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:30 AM ET.

Arbutus Biopharma Stock Down 2.5%

Shares of NASDAQ ABUS opened at $4.25 on Thursday. The business’s 50 day moving average price is $4.32 and its two-hundred day moving average price is $4.42. The company has a market cap of $817.36 million, a PE ratio of -18.48 and a beta of 0.69. Arbutus Biopharma has a twelve month low of $2.70 and a twelve month high of $5.10.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mercer Global Advisors Inc. ADV lifted its position in Arbutus Biopharma by 9.2% during the third quarter. Mercer Global Advisors Inc. ADV now owns 38,959 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 3,280 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Arbutus Biopharma by 6.3% in the second quarter. The Manufacturers Life Insurance Company now owns 59,350 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 3,540 shares during the last quarter. Rafferty Asset Management LLC increased its stake in shares of Arbutus Biopharma by 6.7% during the second quarter. Rafferty Asset Management LLC now owns 88,454 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 5,590 shares during the period. Legal & General Group Plc increased its stake in shares of Arbutus Biopharma by 5.1% during the second quarter. Legal & General Group Plc now owns 124,486 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 6,089 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Arbutus Biopharma by 7.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 89,216 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 6,208 shares during the last quarter. Institutional investors and hedge funds own 43.79% of the company’s stock.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.